

Increase Access to Prostate Cancer Screening

ZERO[®]
PROSTATE CANCER

Get high-risk men screened to save lives and costs

- United States Prostate Cancer in 2024: **New cases: 299,010 | Deaths: 35,250**¹
 - In 2021, **only 17.2% of high-risk men aged 40-85** had a PSA test.²
 - In the last decade, the **metastatic case rate increased 5% per year**, outpacing the overall prostate cancer case rate by an additional 2%.³
- Prostate cancer is often asymptomatic until metastatic, and screening helps detect the disease early when it's most survivable and least costly to treat.



	EARLY STAGE	LATE STAGE	DIFFERENCE
6-YEAR SURVIVAL RATE ⁴	99%	28.7%	70.3%
AVERAGE ANNUAL COST ⁵	\$32,985	\$110,318	\$77,333



Screening saves one life for every 11 to 16 men diagnosed,⁶ but cost-sharing drives men to cut back on screenings,⁷ annual examinations,⁸ and visits to the urologist,⁹ leading to later-stage disease which is **70% less survivable**⁴ and **\$77,333 more costly to treat each year.**⁵

Cost Savings: Removing Prostate Cancer Screening Cost-Sharing for High-Risk Men

- Bipartisan bills removing out-of-pocket costs for prostate cancer screening for high-risk men have been passed in DE, IL, KY, NY, MD, OR, RI, TN, and DC, and are being considered in NJ, OH, PA, TX and VA.
- Fiscal notes for similar bills in Kentucky,¹¹ Maryland,¹² Tennessee,¹³ and Virginia¹⁴ showed **no significant impact on state spending or insurance premiums**, with Maryland's premiums increasing by \$0.35 per person annually following bill passage and Kentucky anticipating **long-term savings via improved screening access**.
- Research suggests that removing cost sharing for prostate cancer screening in these states has led to:
 - **1,042,186 more men screened** every two years, increasing screening by 25%.¹⁵
 - **1,482 metastatic cases prevented and 49,410 more cases detected** in men aged 55-69 over 13 years.¹⁶
 - **\$458,522,910.24 in treatment cost savings** for men aged 55-69 over 13 years.^{5,16}
 - **867 lives saved** of men aged 55-69 over 16 years,¹⁷ including the lives of veterans,¹⁸ Black men,¹⁹ rural residents,²⁰ men with a family history²¹ or genetic predisposition,²² and legislators who are all at-risk.²³

Continued on next page ▶

ZERO[®]
PROSTATE CANCER

 **American Cancer Society**
Cancer Action Network™

Increase Access to Prostate Cancer Screening

ZERO[®]
PROSTATE CANCER



American
Urological
Association



- 1 Cancer Facts & Figures 2024, American Cancer Society.
- 2 Morley, F., Iyer, H. S., Tamimi, R. M., Nanus, D. M., Rebbeck, T. R., & Kensler, K. H. (2024). Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program. *Cancer causes & control : CCC*, 35(3), 509–521. <https://doi.org/10.1007/s10552-023-01807-7>
- 3 Kadeerhan, G., Xue, B., Wu, X.-L., Chen, W.-N., & Wang, D.-W. (2023). Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010-2019 surveillance, epidemiology, and end results. In *Frontiers in Oncology* (Vol. 13). Frontiers Media SA. <https://doi.org/10.3389/fonc.2023.1201753>
- 4 SEER*Explorer: An interactive website for SEER cancer statistics [Internet]. Surveillance Research Program, National Cancer Institute; 2024 Apr 17. [cited 2024 Jun 11]. Available from: <https://seer.cancer.gov/statistics-network/explorer/>. Data source(s): SEER Incidence Data, November 2023 Submission (1975-2021), SEER 22 registries (excluding Illinois and Massachusetts). Expected Survival Life Tables by Socio-Economic Standards.
- 5 McCarvey, N., Gitlin, M., Fadli, E., & Chung, K. C. (2022). Increased healthcare costs by later stage cancer diagnosis. In *BMC Health Services Research* (Vol. 22, Issue 1). Springer Science and Business Media LLC. <https://doi.org/10.1186/s12913-022-08457-6>
- 6 Basourakos, S. P., Gulati, R., Vince, R., Spratt, D. E., Lewicki, P., Hill, A. J., Nyame, Y. A., Cullen, J., Markt, S. C., Barbieri, C. E., Hu, J. C., Trapl, E. S., & Shoag, J. (2022). Harm-to-Benefit of three decades of prostate cancer screening in Black men. *NEJM Evidence*, 1(6). <https://doi.org/10.1056/evidoa2200031>
- 7 Trivedi, A. N., Rakowski, W., & Ayanian, J. Z. (2008). Effect of Cost Sharing on Screening Mammography in Medicare Health Plans. In *New England Journal of Medicine* (Vol. 358, Issue 4, pp. 375–383). Massachusetts Medical Society. <https://doi.org/10.1056/nejmsa070929>
- 8 Cherkin, Daniel C. PhD; Grothaus, Louis MS; Wagner, Edward H. MD, MPH. The Effect of Office Visit Copayments on Utilization in a Health Maintenance Organization. *Medical Care* 27(11):p 1036-1045, November 1989.
- 9 Scitovsky, A. A., & McCall, N. (1977). Coinsurance and the demand for physician services: four years later. *Social security bulletin*, 40(5), 19–27.
- 10 Legislative Budget Board, Cortez, & McGinty, J. (2023). Fiscal Note, 88th Legislative Regular Session. In T. Oliverson, House Committee on Insurance. <https://capitol.texas.gov/tlodocs/88R/fiscal-notes/pdf/HB00118H.pdf#navpanes=0>
- 11 Kentucky Department of Insurance. (2024, February 9). Financial Impact Statement on HB 52. <https://apps.legislature.ky.gov/recorddocuments/note/24RS/hb52/HCS1HM.pdf>
- 12 Steffen, B. (2020, January 28). Request for Cost Estimate to Eliminate Cost Sharing for Prostate Cancer Screening. [https://www.scstatehouse.gov/CommitteeInfo/ProstateCancerStudyCommittee/MHCC%20Transmittal%20Letter%20PSA%20screening%20\(2\).pdf](https://www.scstatehouse.gov/CommitteeInfo/ProstateCancerStudyCommittee/MHCC%20Transmittal%20Letter%20PSA%20screening%20(2).pdf)
- 13 Carsner, K. L. (2024). Fiscal Note HB 2954 - SB 2883. <https://www.capitol.tn.gov/Bills/113/Fiscal/HB2954.pdf>
- 14 Virginia Department of Planning and Budget. (2022). 2022 Fiscal Impact Statement on HB 477. <https://lis.virginia.gov/cgi-bin/legp604.exe?221+oth+HB477F122+PDF>
- 15 Bitler, Marianne P., and Christopher S. Carpenter. 2016. "Health Insurance Mandates, Mammography, and Breast Cancer Diagnoses." *American Economic Journal: Economic Policy*, 8 (3): 39-68.
- 16 US Preventive Services Task Force, Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA* 2018; 319(18):1901–1913.
- 17 Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. *European Urology* 2019; 76(1):43–51.
- 18 Zhu, K., Devesa, S. S., Wu, H., Zahm, S. H., Jatoui, I., Anderson, W. F., Peoples, G. E., Maxwell, L. G., Granger, E., Potter, J. F., & McGlynn, K. A. (2009). Cancer Incidence in the U.S. Military Population: Comparison with Rates from the SEER Program. In *Cancer Epidemiology, Biomarkers & Prevention* (Vol. 18, Issue 6, pp. 1740–1745). American Association for Cancer Research (AACR). <https://doi.org/10.1158/1055-9965.epi-09-0041>
- 19 Powell IJ, Bock CH, Ruterbusch JJ, Sakr W. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. *J Urol*. 2010;183:1792–1796.
- 20 Hu, S., Chang, C.-P., Dodson, M. W., Deshmukh, V., Newman, M., Date, A., Sanchez, A., Lloyd, S., O'Neil, B., & Hashibe, M. (2024). Rural-urban disparities in prostate cancer survival: A population-based study. In *Journal of Clinical Oncology* (Vol. 42, Issue 4_suppl, pp. 267–267). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2024.42.4_suppl.267
- 21 Beebe-Dimmer, J. L., Kapron, A. L., Fraser, A. M., Smith, K. R., & Cooney, K. A. (2020). Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. In *Journal of Clinical Oncology* (Vol. 38, Issue 16, pp. 1807–1813). American Society of Clinical Oncology (ASCO). <https://doi.org/10.1200/jco.19.02808>
- 22 Akbari MR, Wallis CJ, Toi A, et al.: The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer. *Br J Cancer* 111 (6): 1238-40, 2014
- 23 Bijoux, W., Cordina-Duverger, E., Balbolia, S., Lamy, P.-J., Rebillard, X., Tretarre, B., Cenee, S., & Menegaux, F. (2022). Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP). In *Journal of Occupational Medicine and Toxicology* (Vol. 17, Issue 1). Springer Science and Business Media LLC. <https://doi.org/10.1186/s12995-022-00346-2>

© 2024 ZERO[®] Prostate Cancer. All rights reserved.

FOR MORE INFORMATION, PLEASE CONTACT:

Georgia Bates, Manager of State Government Relations & Advocacy for ZERO Prostate Cancer

 georgia@zerocancer.org

 713-898-1283

 zerocancer.org